Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.99M
Last updated: Nov 17, 2026 at 4:10 PM ET
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Statistics
Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market cap of $3.99M and an enterprise value of $2.41M. Its share count is up 107.71% from a year earlier. It holds $1.57M more cash than debt, 39.47% of its market cap.
Total Valuation
Enterprise value is 39.47% below the market cap, as cash exceeds debt.
| Market Cap | $3.99M |
|---|---|
| Enterprise Value | $2.41M |
| Latest price (Nov 17, 2026) | $2.81 |
Key Dates
| Last Earnings Date | Aug 14, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 94.75% over 52 weeks and trades 15.62% below its 50-day average.
| Beta (1Y) | 0.66 |
|---|---|
| 52-Week Change | -94.75% |
| 1-Month Change | -9.65% |
| 3-Month Change | -49.69% |
| 6-Month Change | -70.42% |
| Total Return (1Y) | -94.75% |
| Return vs SPY (1Y) | -106.50% |
| Max Drawdown (1Y) | -97.54% |
| Sharpe Ratio (1Y) | -1.72 |
| Correlation with SPY (1Y) | 0.05 |
| 50-Day Average | $3.33 |
| 200-Day Average | $9.21 |
| 52-Week Range | $2.40 to $141.50 |
| RSI (14 Days) | 44.0 |
| Average Volume (20 Days) | 31.30K |
Financial Position
Current assets cover 1.12x current liabilities, and total debt is 4.80x shareholder equity.
| Current Ratio | 1.12x |
|---|---|
| Quick Ratio | 1.12x |
| Debt / Equity | 4.80x |
| Interest Coverage | -72.16x |
Returns and Efficiency
Return on invested capital is -247.19% and return on equity is -4274.79% over the last 12 months.
| Return on Equity (ROE) | -4274.79% |
|---|---|
| Return on Assets (ROA) | -377.55% |
| Return on Invested Capital (ROIC) | -247.19% |
| Return on Capital Employed (ROCE) | -1501.38% |
Scores
LIMN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | $255 |
| Operating Income | -$4.33M |
| Pretax Income | -$12.85M |
| Net Income | -$12.85M |
| EBIT | -$5.45M |
| Reported EPS (TTM) | -$837.61 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 8.84% of the $3.40M in total assets.
| Cash and Equivalents | $3.02M |
|---|---|
| Total Debt | $1.44M |
| Net Cash | $1.57M |
| Net Cash Per Share | $1.63 |
| Working Capital | $352.04K |
| Shareholder Equity | $300.61K |
| Book Value Per Share | $0.31 |
| Total Assets | $3.40M |
| Total Liabilities | $3.10M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Operating Cash Flow | -$3.97M |
|---|---|
| FCF Per Share | -$2.97 |
| Depreciation and Amortization | $2.07K |
Trailing 12 months through Jun 30, 2026.
Dividends and Yields
LIMN does not pay a dividend.
| Buyback Yield | -131.81% |
|---|---|
| Shareholder Yield | -131.81% |
Stock Splits
The last split was a 1-for-50 reverse split on Aug 21, 2026.
| Last Split Date | Aug 21, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:50 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About LIMN
What is LIMN's market cap?
Liminatus Pharma, Inc. Class A Common Stock has a market cap of $3.99M. Its enterprise value, which adds debt and subtracts cash, is $2.41M.
How many shares of LIMN are outstanding?
Liminatus Pharma, Inc. Class A Common Stock has 967.97K shares outstanding. The count is up 107.71% from a year earlier.
Does LIMN pay a dividend?
No. Liminatus Pharma, Inc. Class A Common Stock does not pay a dividend.
How much debt does LIMN have?
Liminatus Pharma, Inc. Class A Common Stock has $1.44M of total debt and $3.02M of cash and equivalents, a net cash position of $1.57M.
LIMN pages: Overview, Financials, Statistics, Competitors